Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Clemens DL, Lee BY, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA.

PLoS One. 2019 May 10;14(5):e0215607. doi: 10.1371/journal.pone.0215607. eCollection 2019. Erratum in: PLoS One. 2019 May 30;14(5):e0217670.

2.

Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.

Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ho CM, Horwitz MA.

PLoS One. 2018 Nov 14;13(11):e0207469. doi: 10.1371/journal.pone.0207469. eCollection 2018.

3.

Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.

Jia Q, Bowen R, Dillon BJ, Masleša-Galić S, Chang BT, Kaidi AC, Horwitz MA.

Sci Rep. 2018 May 3;8(1):7009. doi: 10.1038/s41598-018-24581-y.

4.
5.

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.

Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA.

Nat Commun. 2017 Jan 24;8:14183. doi: 10.1038/ncomms14183.

6.

Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.

Jia Q, Bowen R, Lee BY, Dillon BJ, Masleša-Galić S, Horwitz MA.

Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28.

7.

Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2009 Jan 14;27(3):441-5. doi: 10.1016/j.vaccine.2008.10.058. Epub 2008 Nov 11.

8.

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA.

Infect Immun. 2008 Nov;76(11):5200-14. doi: 10.1128/IAI.00434-08. Epub 2008 Aug 25.

10.

A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2006 Mar 6;24(10):1593-600. Epub 2005 Oct 11.

11.

Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity.

Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S.

Vaccine. 2006 Jan 23;24(4):443-51. Epub 2005 Aug 11.

13.

A two-plasmid system for stable, selective-pressure-independent expression of multiple extracellular proteins in mycobacteria.

Harth G, Maslesa-Galić S, Horwitz MA.

Microbiology. 2004 Jul;150(Pt 7):2143-51.

PMID:
15256557
15.

Supplemental Content

Loading ...
Support Center